LAM 003

Drug Profile

LAM 003

Alternative Names: LAM-003

Latest Information Update: 13 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Undisclosed
  • Developer LAM Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia

Most Recent Events

  • 16 Jan 2018 Lam Therapeutics initiates enrolment in a phase I trial for Acute myeloid leukaemia in USA (NCT03426605)
  • 30 Nov 2017 Phase-I clinical trials in Acute myeloid leukaemia in USA (PO) (LAM Therapeutics website, Dec 2017)
  • 30 Nov 2017 US FDA clears LAM Therapeutics' IND for LAM 003 for Leukaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top